ABOUT TRAVELERS' DIARRHEA
This year, approximately 55 million international travelers will visit countries where bacteria that cause travelers' diarrhea are endemic, particularly Africa, Asia and Latin America, and about 20 million of those travelers will develop travelers' diarrhea.
A recently completed market study suggested that there is a large market for an effective travelers' diarrhea vaccine, potentially exceeding $750 million annually. If approved, the Iomai vaccine would be the first vaccine for travelers' diarrhea available in the United States.
The impact of travelers' diarrhea goes beyond travelers. The World Health Organization estimates that children in the developing world suffer 200 million episodes of diarrhea caused by ETEC annually, causing 380,000 deaths each year.
ABOUT IOMAI CORPORATION
Iomai Corporation discovers and develops vaccines and immune system
stimulants, delivered via a novel, needle-free technology called
transcutaneous immunization (TCI). TCI, discovered by researchers at the
Walter Reed Army Institute of Research, taps into the unique benefits of a
major group of antigen-presenting cells found in the outer layers of the
skin (Langerhans cells) to generate an enhanced immune response. Iomai is
leveraging TCI to enhance the efficacy of existing vaccines, develop new
vaccines that are viable only through transcutaneous administration and
expand the global vaccine market. Iomai currently has four product
candidates in development: three targeting influenza and pandemic flu and
one to prevent travelers' diarrhea. For more information on Iomai, please
|SOURCE Iomai Corporation|
Copyright©2007 PR Newswire.
All rights reserved